The annual addition of this Roadmap provides a path forward for elected officials, government agencies, and others involved with the allocation of opioid settlement funds.
harm reduction
A Roadmap for Opioid Settlement Funds: Supporting Communities & Ending the Overdose Crisis
New York Guide for Community Advocates on the Opioid Settlement
Vital Strategies, in collaboration with Christine Minhee of OpioidSettlementTracker.com, produced this comprehensive guide on opioid settlement funds to demystify how the state will receive and allocate opioid settlement funds. The goal is to empower community advocates on the ground to effectively understand and engage with the settlement planning and spending process.
CoOP: Integrative buprenorphine delivery – Increasing treatment access and quality to address Maryland’s overdose epidemic (powerpoint)
Integrating buprenorphine prescribing into OTP
Poster of same model.
New York State Office of Addiction Services and Supports – Harm Reduction Is Part of the Treatment Continuum
This is a recording of a training that discusses how to normalize addiction through patient-centered care to improve outcomes and reduce overdose deaths.
Association of Take-Home Naloxone and Opioid Overdose Reversals Performed by Patients in an Opioid Treatment Program
These findings suggest that take-home naloxone supplied to patients in opioid treatment programs may be part of a targeted harm-reduction strategy to reduce negative outcomes associated with opioid overdose in the community.
Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review
Innovative service modifications to adapt to COVID-19 circumstances primarily involved expanded use of telehealth services (e.g., telemedicine visits for buprenorphine, virtual individual or group therapy sessions, provision of donated or publicly available phones), increased take-home medication allowances for methadone and buprenorphine, expanded uptake of long-acting opioid medications (e.g. extended-release buprenorphine and naltrexone), home delivery of services (e.g. MOUD, naloxone and urine drug screening), outreach and makeshift services for delivering MOUD and naloxone, and provision of a safe supply of opioids.
Integration of a Community Opioid Treatment Program into a Federally Qualified Health Center
An opioid treatment program (OTP) and a federally qualified health center (FQHC) partnered to develop and implement an innovative integrated methadone and primary care treatment model. The process for integrating an OTP and FQHC to provide methadone treatment in the primary care setting will be discussed.
Integrating Harm Reduction into Outpatient Opioid Use Disorder Treatment Settings
The objective of this narrative review is to describe strategies for the integration of evidence-based harm reduction principles and interventions into outpatient, primary care–based OUD treatment settings.
Edith Springer – Best practice stances for working with clients who use drugs
A 1996 guidance document produced by Edith Springer, a pioneer of U.S. Harm Reduction
